AI-driven drug developer Absci lines up Jefferies and Goldman talks
Absci (Nasdaq: ABSI), a biopharmaceutical company utilizing generative AI for drug discovery, announced its participation in two investor conferences in June 2026. The company will present at the Jefferies Global Healthcare Conference on June 3rd and the Goldman Sachs 47th Annual Global Healthcare Conference on June 9th. Live and archived webcasts of these presentations will be available on Absci's investor relations website.
Absci (ABSI) price target increased by 11.14% to 8.92
The article reports that the price target for Absci (ABSI) has been increased by 11.14%, raising it to $8.92. This indicates a positive outlook from analysts regarding the company's stock performance.
Absci Corp (ABSI) director Menelas Pangalos adds 37,453 shares in open-market buy
Absci Corp director Menelas N. Pangalos purchased 37,453 shares of the company's common stock at $5.36 per share in an open-market transaction. This increases his direct ownership to 232,308 shares, reflecting a larger personal stake aligned with the company’s equity. The transaction was reported via a Form 4 SEC filing and conducted in accordance with Absci Corp's trading policies.
Insider Buying: Menelas Pangalos Acquires Shares in Absci Corp (ABSI)
Menelas Pangalos, a Director at Absci Corp (ABSI), purchased 37,453 shares of the company on May 13, 2026, increasing his total holdings to 232,308 shares. This acquisition is part of a larger trend of insider buying at Absci Corp, which has seen 7 insider buys and 2 insider sells over the past year. Despite the insider confidence, the stock is considered significantly overvalued based on its GF Value of $0.96 compared to its trading price of $5.36.
HC Wainwright Has Optimistic Outlook of Absci Q3 Earnings
HC Wainwright raised its Q3 2026 EPS estimate for Absci (NASDAQ:ABSI) to a loss of $0.22 per share from $0.23, indicating a slightly more positive view on near-term earnings. Despite this, the broader outlook remains negative, with Absci still expected to post losses through at least 2027. The company's latest earnings results showed a beat on EPS, but revenue significantly missed forecasts, leading to a 7.3% stock decline.
Absci price target raised to $11 from $9 at JonesResearch
JonesResearch analyst Debanjana Chatterjee has raised the price target for Absci (ABSI) from $9 to $11, maintaining a Buy rating. This adjustment follows Absci's Q1 report, with the firm noting that their ABS-201 appears safe and data for androgenetic alopecia is expected in the second half of 2026. The increase reflects confidence in the company's pipeline and clinical catalysts.
JonesTrading Maintains Absci Corp(ABSI.US) With Buy Rating, Raises Target Price to $11
JonesTrading analyst Debanjana Chatterjee has maintained a Buy rating for Absci Corp (ABSI.US) and increased the target price from $9 to $11. This adjustment is based on the analyst's strong track record, boasting a 76.0% success rate and a 53.2% total average return over the past year. The information is provided for informational purposes and should not be considered investment advice.
Absci (NASDAQ:ABSI) Reaches New 52-Week High After Analyst Upgrade
Absci (NASDAQ:ABSI) shares reached a new 52-week high after Truist Financial upgraded its price target from $9 to $11, maintaining a buy rating. The stock traded as high as $6.35, following a previous close of $5.90. Despite mixed analyst sentiment, with a consensus "Moderate Buy" rating, the company recently reported a smaller-than-expected quarterly loss, though revenue was below forecasts.
H.C. Wainwright Maintains Absci Corp(ABSI.US) With Buy Rating, Maintains Target Price $8
H.C. Wainwright analyst Swayampakula Ramakanth has reiterated a Buy rating for Absci Corp (ABSI.US) and maintained a target price of $8. The analyst has a 45.0% success rate and a 19.9% average return over the past year, according to TipRanks data. This information is provided for educational purposes and is not an investment recommendation.
Needham Reiterates Buy Rating on ABSI with Price Target of $7.00
Needham has reiterated its Buy rating for Absci (ABSI) with a consistent price target of $7.00. This decision reflects continued confidence in the company's market potential, as Absci, an AI-powered synthetic biology firm, focuses on revolutionizing therapeutic development. Analysts forecast an average target price of $7.87, suggesting a significant upside from its current trading price, indicating a strong "Outperform" status.
Needham Maintains Absci Corp(ABSI.US) With Buy Rating, Maintains Target Price $7
Needham has reiterated its Buy rating for Absci Corp (ABSI.US) and maintained its price target of $7. This indicates a continued positive outlook on the company's stock performance by the investment firm.
Needham Maintains Absci Corp(ABSI.US) With Buy Rating, Maintains Target Price $7
Needham analyst Gil Blum has reiterated a Buy rating for Absci Corp (ABSI.US), maintaining a target price of $7. According to TipRanks data, Blum has a 44.1% success rate and an average return of 15.5% over the past year. This information is provided for informational purposes and should not be considered investment advice.
Absci Corporation (ABSI) reports Q1 loss, misses revenue estimates
Absci Corporation (ABSI) reported a loss for the first quarter, missing analysts' revenue estimates. The company posted a loss of 32 cents per share, which is wider than analysts' expectations. Revenue for the quarter also fell short of predictions.
Absci Corporation (ABSI) reports Q1 loss, misses revenue estimates
Absci Corporation (ABSI) announced a wider-than-expected loss for the first quarter of 2026, alongside revenue that fell short of analyst estimates. The company reported a net loss of $0.16 per share, exceeding the anticipated loss of $0.13 per share. Revenue for the quarter reached $3.2 million, missing the consensus estimate of $4.3 million.
Absci (NASDAQ:ABSI) Releases Quarterly Earnings Results, Hits Estimates
Absci (NASDAQ:ABSI) reported quarterly earnings, matching EPS estimates at ($0.19) but significantly missing revenue expectations at $0.22 million versus $1.39 million. The company revealed a strategic shift to focus resources on ABS-201 and prolactin-focused programs while de-emphasizing oncology, maintaining a cash runway into the first half of 2028. Following the news, the stock traded down 3.4% to $5.75, with analysts holding a "Hold" consensus rating and a $6.44 target.
Absci (ABSI) posts Q1 2026 results, advances ABS-201 and adds ABS-202
Absci Corporation announced its Q1 2026 financial results, reporting revenue of $0.2 million and a net loss of $29.6 million, while emphasizing pipeline advancements. The company completed single-ascending-dose cohorts and initiated multiple-ascending-dose cohorts for its ABS-201 trial for androgenetic alopecia, with preliminary data expected in Q2 2026. Absci also introduced ABS-202 for inflammation and immunology and plans a Phase 2 endometriosis study for ABS-201, leveraging its cash reserves expected to fund operations into the first half of 2028.
Hair-loss drug trial reaches patient dosing; Absci adds ABS-202
Absci reported its Q1 2026 financial and operating results, including advancements in its ABS-201 hair-loss drug trial, which has begun dosing participants for androgenetic alopecia and showed favorable safety data. The company also expanded its pipeline by adding ABS-202 for an undisclosed inflammation and immunology indication. Despite a decline in revenue and widening net loss, Absci maintains a cash runway into the first half of 2028.
Absci Reports Business Updates and First Quarter 2026 Financial and Operating Results
Absci has announced its business updates and financial and operating results for the first quarter of 2026. This report provides crucial insights into the company's performance, strategic developments, and financial health during the specified period.
Absci (NASDAQ: ABSI) Q1 loss widens as revenue falls to $0.2M
Absci (NASDAQ: ABSI) reported a Q1 2026 net loss of $29.6 million, an increase from $26.3 million in Q1 2025, while revenue fell significantly to $0.2 million from $1.2 million, primarily due to timing of project milestones. Research and development expenses rose to $19.3 million as the company continued to invest in its AI-driven antibody pipeline and advanced lead candidate ABS-201, which is undergoing Phase 1/2a clinical trials for androgenetic alopecia and is planned for a Phase 2 trial in endometriosis. The company maintains $125.7 million in cash, cash equivalents, and marketable securities to support ongoing operations and development.
Absci Reports Business Updates and First Quarter 2026 Financial and Operating Results
Absci Corporation announced business updates and its first-quarter 2026 financial results, highlighting successful dosing in the ABS-201™ HEADLINE trial for androgenetic alopecia and the addition of ABS-202 to its pipeline for an undisclosed inflammation and immunology indication. The company reported a revenue of $0.2 million and a net loss of $29.6 million for the quarter, with cash reserves projected to fund operations into the first half of 2028.
Absci : Corporate Presentation, May 2026
Absci Corporation presented its corporate outlook for May 2026, highlighting its AI-native platform for generative drug design and its differentiated pipeline. The company is advancing ABS-201 for Androgenetic Alopecia (AGA) and Endometriosis, with clinical trials underway and promising preclinical data. Absci projects a significant market opportunity for ABS-201 in AGA, anticipating a novel, convenient, and effective treatment for hair regrowth.
Earnings Flash (ABSI) Absci Corporation Reports Q1 Revenue $200,000
Absci Corporation (ABSI) announced its Q1 revenue was $200,000. This news follows their recent Q4 2025 earnings report and several presentations at healthcare conferences. The company is a clinical-stage biopharmaceutical firm focusing on advancing therapeutics through generative design and AI models.
Absci Corporation (NASDAQ:ABSI) Given Average Recommendation of "Hold" by Brokerages
Absci Corporation (NASDAQ:ABSI) has received an average "Hold" recommendation from brokerages, with an average 12-month price target of $6.44. This comes after the company missed quarterly earnings and revenue expectations significantly. Despite the mixed analyst ratings and financial performance, insider Andreas Busch recently acquired 100,000 shares, and institutional ownership remains strong with increased positions from major investment firms.
Absci Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Absci Corporation announced it granted a non-statutory stock option for 276,200 shares of common stock to a new non-executive employee on May 1, 2026. This inducement grant, approved by the Compensation Committee, is in accordance with Nasdaq Listing Rule 5635(c)(4) and is material to the new employee's acceptance of employment. The stock option has an exercise price of $4.92 per share and vests over four years.
New Absci hire gets option to buy 276,200 shares at $4.92
Absci (Nasdaq: ABSI) granted a non-statutory option for 276,200 shares of its common stock to a newly hired non-executive employee on May 1, 2026. This inducement award, approved by the Compensation Committee, has an exercise price of $4.92 and vests over four years, with 25% vesting after one year and the remainder in monthly installments over 36 months, subject to continued service. The grant is in accordance with Nasdaq Listing Rule 5635(c)(4), aimed at attracting and retaining talent.
Absci Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Absci Corporation announced it granted a non-statutory stock option to a newly-hired non-executive employee for 276,200 shares. This inducement grant, approved by the Compensation Committee, is in accordance with Nasdaq Listing Rule 5635(c)(4) and aims to incentivize the employee. The stock option has an exercise price of $4.92 per share and vests over four years.
ABSI Stock Climbs As Traders Eye New 13D/A Filing
Absci Corporation (ABSI) stock climbed by 13.92% following the filing of an amended Schedule 13D/A, which updated disclosures from a major shareholder. This regulatory update is drawing trader attention to ownership dynamics and institutional interest, rather than new revenue, as the company remains in an early, high-risk biotech stage despite a strong balance sheet. The stock has nearly doubled in a few weeks, indicating strong momentum driven by speculative interest and an AI-driven drug discovery narrative.
Earnings Preview: Absci Corp to Report Financial Results Post-market on May 07
This article announces that Absci Corp (NASDAQ: ABSI) is scheduled to release its financial results after the market closes on May 7. Analysts expect the company to report earnings of $-0.21 per share and revenue of $4.48 million for the quarter. Investors will be looking for updates on future guidance and any growth in revenue.
Earnings Preview: Absci Corp to Report Financial Results Post-market on May 07
Absci Corp is scheduled to report its financial results post-market on May 07. The company is expected to announce an EPS of $-0.26 for the first quarter of 2024, maintaining the previous quarter's estimate. Revenue forecasts are set at $0.94 million, which would represent a significant year-over-year increase but a quarterly decline.
5 Best Biotech Penny Stocks to Buy in 2026
This article lists the top 5 biotech penny stocks to consider buying in 2026, focusing on companies with promising pipelines and financial positions. It highlights Absci Corporation (NASDAQ: ABSI) as a key player, detailing its progress in AI-designed therapeutics for androgenetic alopecia and endometriosis, recent financial results, and future partnership expectations. The article emphasizes Absci's strong balance sheet and solid internal pipeline advancements.
Absci (ABSI) Expected to Announce Earnings on Thursday
Absci (NASDAQ:ABSI) is scheduled to announce its Q1 2026 earnings after the market closes on Thursday, May 7th. Analysts anticipate the company will report earnings of ($0.19) per share and revenue of $1.4290 million. The report also details previous financial performance, stock price performance, recent analyst ratings, and significant insider and institutional investor activity.
H.C. Wainwright Maintains Absci Corp(ABSI.US) With Buy Rating, Maintains Target Price $8
H.C. Wainwright has reaffirmed its Buy rating on Absci Corp (ABSI.US) and maintained its target price of $8. This indicates the firm's continued positive outlook on the company's stock performance.
H.C. Wainwright Maintains Absci Corp(ABSI.US) With Buy Rating, Maintains Target Price $8
H.C. Wainwright has reiterated its Buy rating for Absci Corp (ABSI.US), maintaining a target price of $8. This indicates the firm's continued positive outlook on the company's stock performance and valuation.
H.C. Wainwright reiterates Absci stock rating on hair loss data By Investing.com
H.C. Wainwright reiterated a Buy rating and an $8.00 price target on Absci Corp. after positive hair loss treatment data from competitor Veradermics. While Absci's financials for Q4 2025 missed expectations, the firm believes Absci's ABS-201 could be a best-in-class therapy if it surpasses a new benchmark for hair growth. KeyBanc also maintains optimism on the hair-loss market, estimating it as a $40 billion opportunity.
12 Health Care Stocks Moving In Monday's Intraday Session
This article lists 12 healthcare stocks experiencing significant movement during Monday's intraday session, categorizing them as gainers or losers. It provides details on the percentage change, current stock price, and market capitalization for each company mentioned. The content was generated by Benzinga's automated engine and reviewed by an editor.
Absci Corp Establishes Advisory Board to Advance Endometriosis Drug
Absci Corporation has formed an advisory board to guide clinical research for ABS-201, its anti-prolactin receptor antibody drug program for endometriosis. This initiative aims to provide a novel treatment for endometriosis that doesn't affect fertility, unlike current hormonal therapies. The company plans to start Phase 2 clinical trials by Q4 2026, with interim data expected in H2 2027, and analysts have a strongly bullish outlook on the stock.
Absci Corp. (ABSI) Offering Impressive Upside to Potential Investors
Absci Corp. (ABSI) is highlighted as one of the 10 most shorted penny stocks with a strongly bullish consensus sentiment from analysts, projecting over 92% upside. The company is developing ABS-201, an anti-prolactin receptor antibody drug for endometriosis, with Phase 2 trials expected to begin by Q4 2026. Absci is working with an advisory board including experts from top medical institutions and aims to offer a novel treatment for endometriosis that doesn't compromise fertility.
Absci Corp. (ABSI) Offering Impressive Upside to Potential Investors
Absci Corp. (NASDAQ: ABSI) is identified as one of the 10 most shorted penny stocks, carrying a strongly bullish consensus sentiment from analysts with a median 1-year target price suggesting over 92% upside. The company is developing ABS-201, an anti-prolactin receptor antibody drug for endometriosis, with planned Phase 2 trials by Q4 2026. This novel therapy aims to treat endometriosis without affecting ovulation, differentiating it from current hormone-based treatments.
10 Most Shorted Penny Stocks to Buy
This article identifies Absci Corp. (NASDAQ: ABSI) as one of the 10 most shorted penny stocks to consider. The company is developing ABS-201, an anti-prolactin receptor antibody drug for endometriosis, with encouraging analyst sentiment and a significant upside potential. Absci has formed an advisory board with experts from leading institutions and plans to begin Phase 2 trials by Q4 2026, targeting a novel pathway to treat endometriosis without affecting fertility.
Absci Corporation (ABSI) Reports Q3 Loss, Lags Revenue Estimates
This article from Zacks Equity Research reports that Absci Corporation (ABSI) posted a wider-than-expected loss in Q3 and also missed revenue estimates. Despite the quarterly performance, the company's shares are up 36.1% year-to-date.
Needham Maintains Absci Corp(ABSI.US) With Buy Rating, Maintains Target Price $7
Needham has reaffirmed its Buy rating for Absci Corp (ABSI.US) and maintained its price target of $7. This indicates a continued positive outlook from the firm regarding Absci Corp's stock performance and future prospects.
Absci to Report Business Updates and First Quarter 2026 Financial and Operating Results on May 7, 2026
Absci Corporation (Nasdaq: ABSI), a clinical-stage biopharmaceutical company, announced it will report its business updates and first quarter 2026 financial and operating results on May 7, 2026, after market close. A webcast conference call will follow at 4:30 p.m. ET to discuss developments and outlook. The company is advancing drug discovery with generative AI and has its own pipeline, including ABS-201 for hair regrowth and endometriosis treatment.
Absci (NASDAQ:ABSI) Shares Up 7.7% - Should You Buy?
Absci (NASDAQ:ABSI) shares rose 7.7% on Thursday, reaching $3.965, though trading volume was below average. Despite this increase, analyst opinions are mixed, with Needham reiterating a Buy rating while Morgan Stanley downgraded the stock to Equal Weight and Weiss Ratings issued a Sell. The company reported a significant earnings and revenue miss for the last quarter, coupled with deeply negative margins, though recent insider activity shows both selling by the CEO and a substantial purchase by another insider.
Absci sets May 7 webcast for Q1 results and business update
Absci (Nasdaq: ABSI) will report its Q1 2026 financial and operating results and provide business updates after market close on May 7, 2026. The company will host a webcast and conference call at 4:30 p.m. ET / 1:30 p.m. PT to discuss developments, financial performance, and outlook. A live audio webcast and replay will be accessible on Absci's investor relations website.
Absci Corporation (ABSI) reports Q4 loss, misses revenue estimates
Absci Corporation (ABSI) announced a Q4 loss, missing revenue estimates. The company reported a net loss of $0.18 per share and revenue of $4.73 million for the quarter. Despite the revenue miss, shares saw a slight increase in after-hours trading.
Absci (NASDAQ: ABSI) sets 2026 virtual vote, highlights ABS-201 and Origin-1 AI
Absci Corporation has released its 2026 proxy statement, announcing a virtual annual meeting on June 4, 2026, where stockholders will vote on electing two Class II directors and ratifying Ernst & Young LLP as auditor. The company highlighted significant progress with its AI-designed antibody, ABS-201, which advanced from discovery to clinic in two years for approximately $15 million, targeting androgenetic alopecia and endometriosis. Absci also introduced its new Origin-1 AI model for de novo antibody design, aiming to drive internal pipeline programs and partnerships.
ABSI Stock Climbs As AI Drug Program Gains Traction
Absci Corporation's stock (ABSI) climbed 8.8% due to optimism surrounding its AI-driven drug discovery program, ABS-201, despite a Q4 EPS and revenue miss. The company announced rapid, low-cost advancement of ABS-201 in clinical trials, with plans for interim proof-of-concept data in 2H26 and a Phase 2 endometriosis trial by Q4 2026. Morgan Stanley maintained an Equal Weight rating, slightly trimming its price target, indicating continued Street respect for Absci's AI platform and pipeline.
We Think Absci (NASDAQ:ABSI) Needs To Drive Business Growth Carefully
This article evaluates the growth trajectory of Absci (NASDAQ:ABSI), emphasizing that while the company has achieved significant revenue growth, its substantial losses and cash burn necessitate careful management. It highlights the importance of balancing growth with financial sustainability to gain investor confidence.
Absci Corp | SCHEDULE 13D/A: Others
This document, a SCHEDULE 13D/A filing for Absci Corp, indicates a change or amendment in beneficial ownership by certain entities. It primarily serves as a regulatory update detailing ownership stakes.
Absci (Nasdaq:ABSI) - Stock Analysis
This Simply Wall St report provides an analysis of Absci (Nasdaq:ABSI), highlighting its current stock price, analyst consensus target, and fair value. The company, a clinical-stage biopharmaceutical firm, is noted for its AI-driven drug discovery platform and pipeline development for conditions like inflammatory bowel disease and androgenetic alopecia. The article also provides a summary of its financial health, growth forecasts, and recent news and updates.
